<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2016-12-1-66-71</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-1203</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INNOVATIVE CARDIOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИННОВАЦИОННАЯ КАРДИОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>Gut microbiota – a new companion on the path of cardiovascular diseases progression: surprising roles of long-time neighbors</article-title><trans-title-group xml:lang="ru"><trans-title>КИШЕЧНАЯ МИКРОБИОТА – НОВЫЙ СПУТНИК НА МАРШРУТЕ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: НЕОЖИДАННЫЕ РОЛИ СТАРЫХ СОСЕДЕЙ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, первый заместитель директора по научной и лечебной работе ГНИЦ ПМ</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кабурова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaburova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>клинический ординатор кафедры факультетской терапии ПМГМУ им. И.М. Сеченова</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины 101990, Москва, Россия, Петроверигский пер., 10 стр.3</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова 119991, Москва, ул. Трубецкая, 8, стр. 2</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University. Trubetskaya ul. 8-2, Moscow, 119991, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>03</month><year>2016</year></pub-date><volume>12</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Drapkina O.M., Kaburova A.N., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Драпкина О.М., Кабурова А.Н.</copyright-holder><copyright-holder xml:lang="en">Drapkina O.M., Kaburova A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/1203">https://www.rpcardio.online/jour/article/view/1203</self-uri><abstract><p>The last decade is marked by the significant reinterpretation of the gut microbiota contribution to chronic disease progression. The researchers’ careful attention is focused on improving the understanding of the metabolic pathways of two dietary compounds – choline and L-carnitine, which stand at the origins of trimethylamine N-oxide (TMAO) formation. This small molecule of great expectations has gained an impressive appreciation due to its ability to promote atherogenesis, and thus increasing the risk of major adverse cardiovascular events and affecting patients’ prognosis. This paper aims to discuss updated concept of microbiota-dependent cardiometabolic consequences of consumption of food rich in quaternary amines as well as to touch upon the currently existing interventions in TMAO production, their limitations and future scientific directions.</p></abstract><trans-abstract xml:lang="ru"><p>Последнее десятилетие характеризуется значимой переоценкой причастности бактерий кишечника к прогрессированию хронических заболеваний. Пристальное внимание исследователей сконцентрировано на совершенствовании понимания метаболических путей двух компонентов пищи – холина и L-карнитина, которые стоят у истоков формирования триметил-N-оксида (ТМАО). Эта небольшая молекула получила признание в связи с ее способностью влиять на атерогенез, увеличивая, таким образом, риск основных сердечно-сосудистых событий и ухудшая прогноз пациентов. Данная работа нацелена на обcуждение обновленной концепции зависимых от микробиоты кардиометаболических последствий употребления продуктов, богатых четвертичными аминами, а также затрагивает существующие способы влияния на образование ТМАО, их ограничения и направления будущих исследований в этой области.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>триметил-N-оксид</kwd><kwd>микробиота</kwd><kwd>атеросклероз</kwd><kwd>метаболизм</kwd><kwd>сердечно-сосудистые маркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>trimethylamine N-oxide</kwd><kwd>microbiota</kwd><kwd>atherosclerosis</kwd><kwd>metabolism</kwd><kwd>cardiovascular markers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007; 116(15): 1714-24.</mixed-citation><mixed-citation xml:lang="en">Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007; 116(15): 1714-24.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zubareva MY, Rozhkova TA, Gorbunova NB, et al. Residual (remaining) risk in patients with very high risk with atherogenic dyslipidemia, are on statin therapy. A prospective study "CRYSTAL". Part 1: The purpose, tasks, design and initial properties included patients. Ateroskleroz i dislipidemii 2013; 1 (10): 26-34. In Russian (Зубарева М.Ю., Рожкова Т. А., Горнякова Н. Б., и др. Резидуальный (остаточный) риск у нездоровых очень высочайшего риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование «КРИСТАЛЛ». Часть 1: Цель, задачки, дизайн и начальные свойства включенных пациентов. Атеросклероз и дислипидемии 2013;1(10):26-34).</mixed-citation><mixed-citation xml:lang="en">Zubareva MY, Rozhkova TA, Gorbunova NB, et al. Residual (remaining) risk in patients with very high risk with atherogenic dyslipidemia, are on statin therapy. A prospective study "CRYSTAL". Part 1: The purpose, tasks, design and initial properties included patients. Ateroskleroz i dislipidemii 2013; 1 (10): 26-34. In Russian (Зубарева М.Ю., Рожкова Т. А., Горнякова Н. Б., и др. Резидуальный (остаточный) риск у нездоровых очень высочайшего риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование «КРИСТАЛЛ». Часть 1: Цель, задачки, дизайн и начальные свойства включенных пациентов. Атеросклероз и дислипидемии 2013;1(10):26-34).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21):2195-207.</mixed-citation><mixed-citation xml:lang="en">Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21):2195-207.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTeRHeART study): case-control study. Lancet 2004;364(9438): 937-52.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTeRHeART study): case-control study. Lancet 2004;364(9438): 937-52.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Turnbaugh PJ, Ley RE, Hamady M et al. The human microbiome project. Nature 2007; 449(7164): 804-10.</mixed-citation><mixed-citation xml:lang="en">Turnbaugh PJ, Ley RE, Hamady M et al. The human microbiome project. Nature 2007; 449(7164): 804-10.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Patel SS, Malakouti M, Cortez MD, et al. Is the gut microbiome the next target for atherosclerosis? JSM Clin Case Rep 2014; 2(5):1055.</mixed-citation><mixed-citation xml:lang="en">Patel SS, Malakouti M, Cortez MD, et al. Is the gut microbiome the next target for atherosclerosis? JSM Clin Case Rep 2014; 2(5):1055.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Vinje S, Stroes E, Nieuwdorp M, et al. The gut microbiome as novel cardio-metabolic target: the time has come! Eur Heart J 2014;35(14):883-7.</mixed-citation><mixed-citation xml:lang="en">Vinje S, Stroes E, Nieuwdorp M, et al. The gut microbiome as novel cardio-metabolic target: the time has come! Eur Heart J 2014;35(14):883-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brown JM, Hazen SL. Meta-organismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol 2014; 25(1):48-53.</mixed-citation><mixed-citation xml:lang="en">Brown JM, Hazen SL. Meta-organismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol 2014; 25(1):48-53.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Backhead F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101(44):15718-23.</mixed-citation><mixed-citation xml:lang="en">Backhead F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101(44):15718-23.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010;51(5):1101-12.</mixed-citation><mixed-citation xml:lang="en">Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010;51(5):1101-12.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Delzenne NM, Cani PD. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011;11(3):154-9.</mixed-citation><mixed-citation xml:lang="en">Delzenne NM, Cani PD. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011;11(3):154-9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Aron-Wisnewsky J, Gaborit B, Dutour A, et al. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19(4):338-48.</mixed-citation><mixed-citation xml:lang="en">Aron-Wisnewsky J, Gaborit B, Dutour A, et al. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19(4):338-48.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Griffin JL, Scott J, Nicholson JK. The influence of pharmacogenetics on fatty liver disease in the Wistar and Kyoto rats: A combined transcriptomic and metabolomic study. J Proteome Res 2007;6(1):54-61.</mixed-citation><mixed-citation xml:lang="en">Griffin JL, Scott J, Nicholson JK. The influence of pharmacogenetics on fatty liver disease in the Wistar and Kyoto rats: A combined transcriptomic and metabolomic study. J Proteome Res 2007;6(1):54-61.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97-101.</mixed-citation><mixed-citation xml:lang="en">Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97-101.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sjögren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res. 2012;27(6):1357-67.</mixed-citation><mixed-citation xml:lang="en">Sjögren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res. 2012;27(6):1357-67.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012;126(9):1110-20.</mixed-citation><mixed-citation xml:lang="en">Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012;126(9):1110-20.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tremaroli V, Bachhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489 (7415):242-9.</mixed-citation><mixed-citation xml:lang="en">Tremaroli V, Bachhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489 (7415):242-9.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lozupone CA, Stombaugh JI, Gordon JI et al. Diversity, Stability and resilience of the human gut microbiota. Nature 2012; 489 (7415): 220-30</mixed-citation><mixed-citation xml:lang="en">Lozupone CA, Stombaugh JI, Gordon JI et al. Diversity, Stability and resilience of the human gut microbiota. Nature 2012; 489 (7415): 220-30</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroecterol 2010; 44 (Suppl. 1): 16-8.</mixed-citation><mixed-citation xml:lang="en">Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroecterol 2010; 44 (Suppl. 1): 16-8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human microbiota. Science 2013; 341(6141): 1237439.</mixed-citation><mixed-citation xml:lang="en">Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human microbiota. Science 2013; 341(6141): 1237439.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature 2014;509(7500):357-60.</mixed-citation><mixed-citation xml:lang="en">Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature 2014;509(7500):357-60.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. MetaHIT Consortium. Nature 2010;464(7285):59-65.</mixed-citation><mixed-citation xml:lang="en">Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. MetaHIT Consortium. Nature 2010;464(7285):59-65.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kostyukevich OI. Influence of intestinal microflora on human health. From Pathogenesis to modern methods of correction of dysbiosis. Rossiyskiy meditsinskiy zhurnal 2011; 5: 304-8. In Russian (Костюкевич О.И. Влияние кишечной микрофлоры на здоровье человека. От патогенеза к современным методам коррекции дисбиоза. Российский медицинский журнал 2011; 5:304-8).</mixed-citation><mixed-citation xml:lang="en">Kostyukevich OI. Influence of intestinal microflora on human health. From Pathogenesis to modern methods of correction of dysbiosis. Rossiyskiy meditsinskiy zhurnal 2011; 5: 304-8. In Russian (Костюкевич О.И. Влияние кишечной микрофлоры на здоровье человека. От патогенеза к современным методам коррекции дисбиоза. Российский медицинский журнал 2011; 5:304-8).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kushnir IE. Intestinal microbiota and human health. Modern approaches to intestinal dysbiosis correction. Zdorov'e Ukrainy 2015; 1: 41-3. In Russian (Кушнир И.Э. Микробиота кишечника и здоровье человека. Современные подходы к коррекции дисбиоза кишечника. Здоровье Украины 2015;1:41-3).</mixed-citation><mixed-citation xml:lang="en">Kushnir IE. Intestinal microbiota and human health. Modern approaches to intestinal dysbiosis correction. Zdorov'e Ukrainy 2015; 1: 41-3. In Russian (Кушнир И.Э. Микробиота кишечника и здоровье человека. Современные подходы к коррекции дисбиоза кишечника. Здоровье Украины 2015;1:41-3).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014;124(10):4204-11.</mixed-citation><mixed-citation xml:lang="en">Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014;124(10):4204-11.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Micha R, Wallace SR, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010; 121(21):2271-83.</mixed-citation><mixed-citation xml:lang="en">Micha R, Wallace SR, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010; 121(21):2271-83.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.</mixed-citation><mixed-citation xml:lang="en">Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bennett BJ, De Aguiar Vallim TQ, Wang Z et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metabolism 2013; 17(1):49-60.</mixed-citation><mixed-citation xml:lang="en">Bennett BJ, De Aguiar Vallim TQ, Wang Z et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metabolism 2013; 17(1):49-60.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Tang WH, Wang Z, Levison BS et al. Intestinal Microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-84.</mixed-citation><mixed-citation xml:lang="en">Tang WH, Wang Z, Levison BS et al. Intestinal Microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-84.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Prospective Studies collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-39.</mixed-citation><mixed-citation xml:lang="en">Prospective Studies collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-39.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite, trimethylamine-N-oxide, in parents with heart failure: refining the gut hypothesis. О Am Coll Cardiol 2013; 64(18):1908-14.</mixed-citation><mixed-citation xml:lang="en">Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite, trimethylamine-N-oxide, in parents with heart failure: refining the gut hypothesis. О Am Coll Cardiol 2013; 64(18):1908-14.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Bell JD, Lee JA, Lee HA et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096(2):101-7.</mixed-citation><mixed-citation xml:lang="en">Bell JD, Lee JA, Lee HA et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096(2):101-7.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rhee EP, Clish CB, Ghorbani A, et al. A combines epidemiologic and metabolomics approach improves CKD prediction. О Am Soc Nephrol 2013;24(8):1330-38.</mixed-citation><mixed-citation xml:lang="en">Rhee EP, Clish CB, Ghorbani A, et al. A combines epidemiologic and metabolomics approach improves CKD prediction. О Am Soc Nephrol 2013;24(8):1330-38.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gao X, Liu X, Xu J, et al. Dietary trimethylamine-N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 2014:118(4):476-81.</mixed-citation><mixed-citation xml:lang="en">Gao X, Liu X, Xu J, et al. Dietary trimethylamine-N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 2014:118(4):476-81.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ierardi E, Sorrentino C, Principi M, et al. Intestinal microbial metabolism of phosphatidylchline: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr 2015;4(4):289-92.</mixed-citation><mixed-citation xml:lang="en">Ierardi E, Sorrentino C, Principi M, et al. Intestinal microbial metabolism of phosphatidylchline: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr 2015;4(4):289-92.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19(5):576-85.</mixed-citation><mixed-citation xml:lang="en">Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19(5):576-85.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D, Xia M, Yan X, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res 2012; 111(8):967-81.</mixed-citation><mixed-citation xml:lang="en">Wang D, Xia M, Yan X, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res 2012; 111(8):967-81.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011;34(1):3-15.</mixed-citation><mixed-citation xml:lang="en">Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011;34(1):3-15.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103(33):12511-6.</mixed-citation><mixed-citation xml:lang="en">Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103(33):12511-6.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Bain MA, Faull R, Milne RW, et al. Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 2006;7(7):811-6.</mixed-citation><mixed-citation xml:lang="en">Bain MA, Faull R, Milne RW, et al. Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 2006;7(7):811-6.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Marcovina SM, Sirtori C, Peracino A, et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res 2013;161(2):73-84.</mixed-citation><mixed-citation xml:lang="en">Marcovina SM, Sirtori C, Peracino A, et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res 2013;161(2):73-84.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012; 172(7):555-63.</mixed-citation><mixed-citation xml:lang="en">Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012; 172(7):555-63.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559-63.</mixed-citation><mixed-citation xml:lang="en">David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559-63.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Lekawanvijit S, Kumfu S, Wang BH, et al. The uremic toxin absorbent AST-120 abogates cardiorenal injury following myocardial infarction. PLoS One 2013;8(12):e83687.</mixed-citation><mixed-citation xml:lang="en">Lekawanvijit S, Kumfu S, Wang BH, et al. The uremic toxin absorbent AST-120 abogates cardiorenal injury following myocardial infarction. PLoS One 2013;8(12):e83687.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Ito S, Higuchi Y, Yagi Y, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013;93(6):837-45.</mixed-citation><mixed-citation xml:lang="en">Ito S, Higuchi Y, Yagi Y, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013;93(6):837-45.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3):979-84.</mixed-citation><mixed-citation xml:lang="en">Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3):979-84.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Тurnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.</mixed-citation><mixed-citation xml:lang="en">Тurnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Gregory JC, Buffa JA, Org E, et al. Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation. J Biol Chem 2015;290(9):5647-60.</mixed-citation><mixed-citation xml:lang="en">Gregory JC, Buffa JA, Org E, et al. Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation. J Biol Chem 2015;290(9):5647-60.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Serino M, Blasco-Baque V, Nicolas S, et al. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep 2014; 16(11):540.</mixed-citation><mixed-citation xml:lang="en">Serino M, Blasco-Baque V, Nicolas S, et al. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep 2014; 16(11):540.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Messenger J, Clark S, Massick S, et al. A review of trimethylaminuria: (fish odor syndrome). О Clin Aesthet Dermatol 2013;6(11):45-8.</mixed-citation><mixed-citation xml:lang="en">Messenger J, Clark S, Massick S, et al. A review of trimethylaminuria: (fish odor syndrome). О Clin Aesthet Dermatol 2013;6(11):45-8.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Hartiala J, Bennett BJ, Tang WH, et al. Comparative genome-wide association studies in mice and humans for trimethylamine-N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol 2014;34(6):1307-13.</mixed-citation><mixed-citation xml:lang="en">Hartiala J, Bennett BJ, Tang WH, et al. Comparative genome-wide association studies in mice and humans for trimethylamine-N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol 2014;34(6):1307-13.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
